EUVIMEDEUVIMED entdecken
Crossref

A Herpes Simplex Virus Type‐1‐Derived Influenza Vaccine Induces Balanced Adaptive Immune Responses and Protects Mice From Lethal Influenza Virus Challenge

Paul J F Rider, Harrison Dulin, Ifeanyi K Uche, Michael C McGee, Weishan Huang, Konstantin G Kousoulas iD, Rong Hai iD

Journal of Medical Virology · 2024

DOI: 10.1002/jmv.70067 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Medical Virology, 2024. Verfasst von Paul J F Rider und 6 weiteren Autor:innen. Beteiligte Einrichtung: Division of Biotechnology and Molecular Medicine Department of Pathobiological Sciences, School of Veterinary Medicine, Louisiana State University, B…. Hauptthemen laut MEDLINE: Influenza Vaccines, Adaptive Immunity, Antibodies, Viral, Orthomyxoviridae Infections. Die Arbeit nennt 53 Literaturangaben. Gefördert von: This research was supported by the National Institute of Allergy and Infectious Diseases., NIAID NIH HHS, NIGMS NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Influenza virus is a major respiratory viral pathogen responsible for the deaths of hundreds of thousands worldwide each year. Current vaccines provide protection primarily by inducing strain‐specific antibody responses with the requirement of a match between vaccine strains and circulating strains. It has been suggested that anti‐influenza T‐cell responses, in addition to antibody responses may provide the broadest protection against different flu strains. Therefore, to address this urgent need, it is desirable to develop a vaccine candidate with an ability to induce balanced adaptive immunity including cell mediated immune responses. Here, we explored the potential of VC2, a well‐characterized Herpes Simplex Virus type 1 vaccine vector, as a live attenuated influenza vaccine candidate. We generated a recombinant VC2 virus expressing the influenza A hemagglutinin protein. We show that this virus is capable of generating potent and specific anti‐influenza humoral and cell‐mediated immune responses. We further show that a single vaccination with the VC2‐derived influenza vaccine protects mice from lethal challenge with influenza virus. Our data support the continued development of VC2‐derived influenza vaccines for protection of human populations from both seasonal and pandemic strains of influenza. Finally, our results support the potential of VC2‐derived vaccines as a platform for the rapid development of vaccines against emerging and established pathogens, particularly respiratory pathogens.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Influenza VaccinesAdaptive ImmunityAntibodies, ViralOrthomyxoviridae InfectionsHerpesvirus 1, HumanVaccines, AttenuatedMice, Inbred BALB CAnimalsMiceFemaleHemagglutinin Glycoproteins, Influenza VirusVaccines, SyntheticImmunity, CellularDisease Models, AnimalHumansSurvival AnalysisGenetic Vectors

Stichwörter der Autor:innen

cell‐mediated immunitydisease controlimmune responsesinfluenza virusvaccines/vaccine strainsvirus classification

Substanzen

Influenza VaccinesAntibodies, ViralVaccines, AttenuatedHemagglutinin Glycoproteins, Influenza VirusVaccines, Synthetic

Autor:innen und Institutionen

  • Division of Biotechnology and Molecular Medicine Department of Pathobiological Sciences, School of Veterinary Medicine, Louisiana State University, Baton Rouge, Louisiana, USA.
  • Department of Pathobiological Sciences, School of Veterinary Medicine, Louisiana State University, Baton Rouge, Louisiana, USA.
  • Department of Microbiology and Plant Pathology, University of California, Riverside, California, USA.
  • Department of Microbiology and Immunology, College of Veterinary Medicine, Cornell University, Ithaca, New York, USA.

ORCID-Profile: Konstantin G Kousoulas, Rong Hai

Förderung

  • This research was supported by the National Institute of Allergy and Infectious Diseases.
  • NIAID NIH HHS
  • NIGMS NIH HHS
  • National Institute of Allergy and Infectious Diseases

Zitieren

APA

Rider, P. J. F., Dulin, H., Uche, I. K., McGee, M. C., Huang, W., Kousoulas, K. G., & Hai, R. (2024). A Herpes Simplex Virus Type‐1‐Derived Influenza Vaccine Induces Balanced Adaptive Immune Responses and Protects Mice From Lethal Influenza Virus Challenge. Journal of Medical Virology. https://doi.org/10.1002/jmv.70067

Vancouver

Rider PJF, Dulin H, Uche IK, McGee MC, Huang W, Kousoulas KG, et al. A Herpes Simplex Virus Type‐1‐Derived Influenza Vaccine Induces Balanced Adaptive Immune Responses and Protects Mice From Lethal Influenza Virus Challenge. Journal of Medical Virology. 2024. doi:10.1002/jmv.70067

BibTeX
@article{Rider2024,
  author = {Rider, Paul J F and Dulin, Harrison and Uche, Ifeanyi K and McGee, Michael C and Huang, Weishan and Kousoulas, Konstantin G and Hai, Rong},
  title = {A Herpes Simplex Virus Type‐1‐Derived Influenza Vaccine Induces Balanced Adaptive Immune Responses and Protects Mice From Lethal Influenza Virus Challenge},
  journal = {Journal of Medical Virology},
  year = {2024},
  doi = {10.1002/jmv.70067}
}
Kostenlos starten →